An observational study in GVHD,Acute, Ulcerative Colitis and Morbus Crohn, sponsored by University of Freiburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by University of Freiburg · Observational
This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD is characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal dysbiosis, which contribute to disease pathogenesis. Defensins are endogenous epithelial cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape the intestinal microbiota composition and contribute to host immunoregulation. Deregulated expression of defensins has been reported in patients with colitis, including Chron's Disease and ulcerative colitis.
In this study, the investigators aim to analyze the expression of defensins in the intestine of patients with acute GVHD to study whether it is deregulated. The results will be valuable to study the role of defensins during acute GVHD pathogenesis or as potential biomarkers for disease activity.
1,073 studies on the registry are indexed under Colitis; 133 are open to participants now.
This study's enrollment of 80 is below the median of 105 across 248 observational studies indexed under Colitis.
Browse Colitis studies →University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients who underwent diagnostic endoscopy
Exclusion Criteria:
Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
Patients with active colitis
Patients with acute gastrointestinal (GI) GVHD
Defensin Expression (mRNA)
Analysis of alpha-defensin and beta-defensin mRNA expression by realtime PCR (qRT-PCR)
Time frame: 3 years
Defensin Expression (peptide)
Analysis of alpha-defensin and beta-defensin levels by immunohistochemistry
Time frame: 3 years
Plan to share: No
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg